Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS-1) is Kun's first member of the ADAMTS metalloproteinase family found in the study of mouse colon adenocarcinoma cell lines in 1997. The human ADAMTS-1 gene is located on the human chromosome 21q21-q22 and encodes a protein of 951 amino acids with a molecular weight of approximately 100 kD.
ADAMTS-1 includes six domains: pre-metalloproteinase, metalloproteinase, a disintegrin-like domain, thrombospondin homologous domain containing TSP-1, spacer and C-terminal thrombin-sensitive protein (TSP) domain, belonging to Zn2+-dependent secreted metalloproteinase, which can be synthesized and secreted by various cells such as macrophages, vascular endothelial cells, smooth muscle cells, and fibroblasts. During the secretion process, the inactive ADAMTS-1 precursor was cleaved into two active forms, 87 kD, and 65 kD, in two successive steps. After ADAMTS-1 is secreted, it is mostly anchored in the extracellular matrix through three TSP repeats and spacers at the C-terminus.
ADAMTS-1 is more widely expressed in mammals. In human normal tissues and organs, the expression level is relatively low, and the tissues with relatively high expression levels are heart, lung, adipose tissue, liver, kidney, brain and skeletal muscle. In growth and development, genitourinary organs formation, ovarian ovulation, follicles. And ADAMTS-1 plays an important role in atherosclerosis (AS), viral myocarditis, and tumors.
Biological Function of ADAMTS-1
The expression of ADAMTS-1 is affected by many factors, among which many inflammatory factors are important factors affecting its expression. For example, inflammatory factors such as TNF-α, IL-1β, and endotoxin can induce the expression of ADAMTS-1. The transforming growth factor TGF-β down-regulates its expression. Various hormones in the body such as androgen, estrogen, progesterone, chorionic gonadotropin and parathyroid hormone can regulate their expression. At the same time, ADAMTS-1 can be involved in the regulation of inflammation by up-regulating the expression of inflammatory factors by inflammatory factors that are secreted by immune cells.
ADAMTS-1 blocks the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2) by binding to the heparin-binding domain of vascular endothelial growth factor (VEGF)-165 at the C-terminus, thereby inhibiting endothelial cell proliferation and angiogenesis. In addition, ADAMTS-1 can also inhibit angiogenesis by activating the matrix glycoproteins TSP-1 and TSP-2, which have anti-angiogenic effects. Martino-Echarri et al. also found that ADAMTS-1 is responsible for the degradation of nidogen-1 and -2 in a mouse model of breast cancer, which helps to enhance the anti-angiogenic response of metalloproteinases. Inagaki et al. found that ADAMTS-1 can block the phosphorylation of VEGFR3 in human dermal lymphatic microvascular endothelial cells HMVEC-dLy, thereby inhibiting lymphangiogenesis.
Chen et al. showed that Adamts1 mainly involves the fat cell lineage stereotype and contributes to the development of obesity. ADAMTS-1 impairs fat cell lineage typing by ECM remodeling by activating the FAK-ERK signaling pathway. In addition, miR-181d up-regulated by BMP4 dominates the Adamts1-ECM-FAK-ERK axis during fat cell lineage typing.
Figure 1. Model of Adamts1-mediated impairment of MSCs adipocyte commitment. (Chen, S. Z. et al. 2016)
ADAMTS-1 and Atherosclerosis
It was found in rat experiments that ADAMTS-1 up-regulated the expression of E-selectin. The establishment of mouse carotid blood flow interruption model also found that ApoE knockout ADAMTS-1 transgenic mice were significantly thicker than the arterial intima of ApoE knockout mice. Therefore, ADAMTS-1 may participate in the occurrence and development of atherosclerosis by degrading versican in the extracellular matrix and promoting the migration of vascular smooth muscle cells.
ADAMTS-1 is a pluripotent enzyme, and immunohistochemical staining of human atherosclerotic plaques revealed high expression of ADAMTS-1. Further studies have shown that ADAMTS-1 can hydrolyze glutamate-alanine bonds in versican, degrade endomembrane matrix proteins, and make VSMCs more likely to invade the inner membrane. At the same time, ADAMTS-1 can also bind to VEGF, block the phosphorylation of VEGFR2, and inhibit the proliferation of endothelial cells.
Therefore, ADAMTS-1 may promote the migration of VSMCs, inhibit the proliferation of endothelial cells, regulate the inflammatory response, initiate and accelerate the occurrence and development of atherosclerosis by degrading polyproteins in the extracellular matrix.
ADAMTS-1 and Coronary Heart Disease
Studies have shown that ADAMTS-1 has a close relationship with various types of coronary heart disease. ADAMTS-1 promotes the formation and progression of atherosclerotic plaques, causing coronary stenosis, resulting in reduced oxygen supply to the coronary arteries. When the coronary blood supply can’t meet the needs of myocardial metabolism, causing acute and temporary ischemia and hypoxia of the myocardium, angina can occur.
It was found through experiments that the expression of ADAMTS-1 mRNA was extremely weak in normal myocardial tissue, but it increased significantly in the early stage of acute myocardial infarction, and its expression increased earlier than MMPs that have been shown to play an important role in ventricular remodeling after myocardial infarction mRNA, and thus Nakamura et al. proposed that ADAMTS-1 plays an important role in ventricular remodeling after acute myocardial infarction and participates in the occurrence and development of ischemic cardiomyopathy.
Hirohata et al. found that hypoxia-induced endothelial cells have the ADAMTS-1 expression, and serum ADAMTS-1 levels are elevated in patients with acute myocardial infarction. Once the arteries are reperfused, serum ADAMTS-1 levels rapidly return to normal levels. ADAMTS-1 may have a unique role in the tumor microenvironment. The study analyzed ADAMTS-1-deficient mice and showed that ADAMTS-1 has a variety of biological functions.
ADAMTS-1 and Cancer
When human fibrosarcoma HT-1080, human prostate cancer DU-145 and Chinese hamster ovary CHO-K1 cells were inoculated subcutaneously in mice, ADAMTS-1 inhibited tumor growth. Studies have shown that overexpression of ADAMTS-1 in a fibrosarcoma model increases angiogenesis-independent tumor growth rates. Furthermore, in contrast to the vasopressor produced by proteolytic cleavage of thrombospondin-1, the enzymatic activity of ADAMTS-1 is required to enhance angiogenesis and promote lung metastasis of Lewis lung cancer and TA3 mouse breast cancer cells.
ADAMTS-1 proteolytic activity can be increased by interaction with fibulin-1, a secretory glycoprotein that also shows tumor and anti-tumor effects. In turn, fibulin-1 can interact with different extracellular matrix components, including known ADAMTS-1 substrates such as nidogen-1 and versican. Tan et al. have shown that fibulin-1 plays a crucial role in the balance of tumor protection and tumor protection function exhibited by ADAMTS-1. In each case, these studies support the effect of ADAMTS-1 catalytic activity on tumor microenvironment remodeling to promote the spread of tumor cells in different types of cancer.
Silva et al. found that immunofluorescence showed colocalization of ADAMTS-1 and nuclear phosphoprotein in MCF-10A, MCF-7 and MDA-MB-231 cell lines. It is indicated that ADAMTS-1 is expressed in the nucleus and nucleolus of three breast cell lines, and the expression level is more abundant than that observed in the cytoplasm.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.